Status
Conditions
Treatments
About
This is a double-blinded, controlled, and randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Full description
The double-blinded, controlled, randomized clinical trial (RCT) will be conducted at 15 centers, at minimum, in the United States and the United Kingdom with the majority of centers in the United States. Up to 184 participants will enter and will self-administer treatments twice daily in their home setting over a period of 12 weeks following a 4 week baseline period. Each participant will complete 6 study visits: 3 visits at the study center and 3 visits completed in the participant's home by video call.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Participant anticipates being unable to attend all visits and complete all study activities.
Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential , who are not abstinent or exclusively in same sex relationships must:
Have a history or prior diagnosis of dementia or or adjusted score ≤ 20 on the Montreal Cognitive Assessment (MoCA) at the screening visit
Have experienced a myocardial infarction, angina, or stroke within the past 12 months, or a transient ischemic attack within the past 6 months.
Are receiving deep brain stimulation therapy.
Are treated with a pump for continuous delivery of dopamine replacement medication.
Have received MRI guided high intensity focused ultrasound within the past 12 months.
Experience frequent falls. (defined as 2 or more falls in the past month related to Parkinson's disease). Parkinson's falls are defined as falls associated with bradykinesia, freezing, turning, change in posture and postural dizziness and do not include accidental falls.
Work night shifts
Use a hearing aid that is implanted or that cannot be easily removed and replaced.
Has any significant co-morbidity or illness which in the opinion of the investigator would prevent safe participation in the study, compliance with protocol requirements or which presents with symptoms that are also common in PD.
Demonstrate suicidality at screening (scores ≥ 4 on the C-SSRS Baseline in section "Suicidal Ideation" (In the past Month)). Participants that respond affirmatively to question 4 or 5 (In the past Month) should receive a referral for mental health counseling according to local site regulations and standards
Use a hearing aid that is implanted or that cannot be easily removed and replaced
Have a cochlear implant or myringotomy tubes
Have chronic that has been ongoing for at least 3 months and causes significant impairment of communication and/or impairment of activities of daily living.
Have previously been diagnosed with traumatic brain injury with ongoing sequalae.
Have been diagnosed with a co-morbid neurological disorder that may present with symptoms overlapping with PD (e.g., stroke, brain tumor, epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, atypical Parkinsonism or aneurysm)
Have been previously diagnosed with either clinically meaningful central vestibular dysfunction (lifetime) or have experienced clinically meaningful peripheral vestibular dysfunction within the last 12 months. For this purpose, clinically meaningful is defined as vestibular dysfunction which causes at least a minimal impairment in the individual activities of daily living (e.g., dressing, bathing, preparing food, conducting household chores, work or recreational activities).
In the Investigator's opinion, currently abuse alcohol, abuse drugs (including legal, illegal or prescribed drugs) or have a history of alcohol or drug dependency within the past 5 years or use any drugs excluded as noted in the Excluded Medications List
Have unresolved complications from a previous surgical procedure at the baseline visits, such as swelling or persistent pain, that requires medical intervention.
Have active ear infections, perforated tympanic membrane or labyrinthitis, as identified by a general ear examination performed by medically qualified Investigators.
Have a recent history of frequent ear infections (≥ 1 per year over the past two years)
Are currently enrolled or have participated in another interventional clinical trial within the last 30 days.
Have had eye surgery within the previous three months or ear surgery within the previous six months.
Have planned surgery scheduled to occur during the study that requires sedation and/or would typically be followed with a prescription for pain management.
Have had eye surgery within the previous three months or ear surgery within the previous six months.
Primary purpose
Allocation
Interventional model
Masking
188 participants in 2 patient groups
Loading...
Central trial contact
Kara Richardson; Jemica Warren
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal